Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
This article was originally published in The Pink Sheet Daily
Executive Summary
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.